These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 10959776)

  • 1. New approaches in the treatment of type 2 diabetes.
    Zhang BB; Moller DE
    Curr Opin Chem Biol; 2000 Aug; 4(4):461-7. PubMed ID: 10959776
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors.
    Holst JJ
    Expert Opin Emerg Drugs; 2004 May; 9(1):155-66. PubMed ID: 15155141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel "second-generation" approaches for the control of type 2 diabetes.
    Rotella DP
    J Med Chem; 2004 Aug; 47(17):4111-2. PubMed ID: 15293978
    [No Abstract]   [Full Text] [Related]  

  • 4. [Future targets in the treatment of type 2 diabetes].
    Stingl H; Roden M
    Wien Klin Wochenschr; 2004 Apr; 116(7-8):217-29. PubMed ID: 15143860
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel pharmacologic agents for type 2 diabetes.
    Uwaifo GI; Ratner RE
    Endocrinol Metab Clin North Am; 2005 Mar; 34(1):155-97. PubMed ID: 15752927
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel insulin sensitizers: pharmacogenomic aspects.
    Otto C; Lehrke M; Göke B
    Pharmacogenomics; 2002 Jan; 3(1):99-116. PubMed ID: 11966407
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel peptides under development for the treatment of type 1 and type 2 diabetes mellitus.
    Baron AD; Kim D; Weyer C
    Curr Drug Targets Immune Endocr Metabol Disord; 2002 Apr; 2(1):63-82. PubMed ID: 12477297
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Evaluation of a thiazolidinedione compound as a new antidiabetic drug].
    Toyota T
    Nihon Rinsho; 2001 Nov; 59(11):2211-8. PubMed ID: 11712410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insulin sensitisation in the treatment of Type 2 diabetes.
    Tadayyon M; Smith SA
    Expert Opin Investig Drugs; 2003 Mar; 12(3):307-24. PubMed ID: 12605557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development and characterization of a glucagon-like peptide 1-albumin conjugate: the ability to activate the glucagon-like peptide 1 receptor in vivo.
    Kim JG; Baggio LL; Bridon DP; Castaigne JP; Robitaille MF; Jetté L; Benquet C; Drucker DJ
    Diabetes; 2003 Mar; 52(3):751-9. PubMed ID: 12606517
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolic stability, receptor binding, cAMP generation, insulin secretion and antihyperglycaemic activity of novel N-terminal Glu9-substituted analogues of glucagon-like peptide-1.
    Green BD; Gault VA; Irwin N; Mooney MH; Bailey CJ; Harriott P; Greer B; Flatt PR; O'Harte FP
    Biol Chem; 2003 Dec; 384(12):1543-51. PubMed ID: 14719796
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [New strategy in type 2 diabetes tested in clinical trials. Glucagon-like peptide 1 (GLP-1) affects basic caused of the disease].
    Ahrén B
    Lakartidningen; 2005 Feb 21-27; 102(8):545-9. PubMed ID: 15786905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Mechanisms of thiazolidinedione derivatives for hypoglycemic and insulin sensitizing effects].
    Sugiyama Y
    Nihon Rinsho; 2002 Sep; 60 Suppl 9():416-21. PubMed ID: 12387027
    [No Abstract]   [Full Text] [Related]  

  • 14. Troglitazone and related compounds: therapeutic potential beyond diabetes.
    Fujiwara T; Horikoshi H
    Life Sci; 2000 Oct; 67(20):2405-16. PubMed ID: 11065164
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glitazones: clinical effects and molecular mechanisms.
    Stumvoll M; Häring HU
    Ann Med; 2002; 34(3):217-24. PubMed ID: 12173692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The incretin approach for diabetes treatment: modulation of islet hormone release by GLP-1 agonism.
    Holst JJ; Orskov C
    Diabetes; 2004 Dec; 53 Suppl 3():S197-204. PubMed ID: 15561911
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Drug treatment of type 2 diabetes].
    Tielmans A; Laloi-Michelin M; Coupaye M; Virally M; Meas T; Guillausseau PJ
    Presse Med; 2007 Feb; 36(2 Pt 2):269-78. PubMed ID: 17258675
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Research advances in the treatment of type 2 diabetes mellitus.
    Caro J; Wishner KL
    Int J Clin Pract Suppl; 1999 Sep; 107():23-33. PubMed ID: 10692729
    [No Abstract]   [Full Text] [Related]  

  • 19. Rebuttal to Deacon and Holst: "Metformin effects on dipeptidyl peptidase IV degradation of glucagon-like peptide-1" versus "Dipeptidyl peptidase inhibition as an approach to the treatment and prevention of type 2 diabetes: a historical perspective".
    Demuth HU; Hinke SA; Pederson RA; McIntosh CH
    Biochem Biophys Res Commun; 2002 Aug; 296(2):229-32. PubMed ID: 12163006
    [No Abstract]   [Full Text] [Related]  

  • 20. The multifaceted potential of glucagon-like peptide-1 as a therapeutic agent.
    Lam NT; Kieffer TJ
    Minerva Endocrinol; 2002 Jun; 27(2):79-93. PubMed ID: 11961501
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.